Patheon signs expanded manufacturing agreement with Merck & Co., Inc.
Patheon designated as a 'preferred supplier' to Merck
RESEARCH TRIANGLE PARK, NC, June 10 /PRNewswire-FirstCall/ - Patheon (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed an expanded contract manufacturing agreement with Merck & Co., Inc. (known as MSD outside of the U.S.A. and Canada).
"We have developed a great partnership with Merck and are very pleased that they have chosen to expand it with this contract manufacturing agreement," said Wes Wheeler, Chief Executive Officer and President of Patheon Inc. "We are 100 percent focused on being the best service provider to our clients. This expanded contract with Merck validates that we are making great progress towards meeting this goal."
The expanded agreement solidifies Patheon as a key preferred supplier to Merck. Patheon's projects and services will be delivered to Merck from eight of Patheon's global facilities.
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of ten facilities, and six development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world. Patheon's integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, strives to ensure that customer products can be launched timely and confidently anywhere in the world.
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be Well. For more information, visit www.merck.com.
SOURCE Patheon Inc.
More by this Source
Patheon Reports Preliminary Unaudited Full-Year Fiscal 2013 Results
Dec 03, 2013, 07:00 ET
Patheon Inc. to be Taken Private for US$9.32 per Share in Cash
Nov 19, 2013, 00:26 ET
Patheon reports fiscal 2013 third quarter results
Sep 05, 2013, 07:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.